Tianyu Group (300702.SZ): The raw material drug potassium amesolate has passed the CDE review.

"Financial APP News, Tianyu shares (300702.SZ) announced that the company's telmisartan potassium raw material drug recently passed the review by the Drug Evaluation Center of the National Medical Products Administration (referred to as "CDE"). Telmisartan potassium is used to treat primary hypertension in adults."